Response to Neoadjuvant Chemoradiotherapy as a Predictor of Long-Term Survival in Patients with Locally Advanced Rectosigmoid Junction Cancer: An Analysis Based On SEER Database

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2023-09-09 DOI:10.18502/ijph.v52i9.13575

Qi Shen, Dandan Liu, Shaojun Liu

{"title":"Response to Neoadjuvant Chemoradiotherapy as a Predictor of Long-Term Survival in Patients with Locally Advanced Rectosigmoid Junction Cancer: An Analysis Based On SEER Database","authors":"Qi Shen, Dandan Liu, Shaojun Liu","doi":"10.18502/ijph.v52i9.13575","DOIUrl":null,"url":null,"abstract":"Background: Neoadjuvant chemoradiotherapy is recommended to locally advanced rectal cancer, especially for the lower and middle ones. However, the role of neoadjuvant chemoradiotherapy in rectosigmoid junction cancer remains undetermined. We investigated whether patients with a good response to neoadjuvant chemoradiotherapy will have a relatively better long-term survival compared with those with no response. Methods: Overall, 1325 patients diagnosed with locally advanced rectosigmoid junction cancer from Surveillance, Epidemiology, and End-Results (SEER) cancer registry database (2004-2014, America) were selected. All of them had received neoadjuvant chemoradiotherapy and were evaluated by Collaborative Stage Data Collection System. We performed Kaplan–Meier univariate analysis and Cox regression multivariate analysis models to estimate the potential prognostic factors of long-term survival outcomes. Response to neoadjuvant chemoradiotherapy and histological type of tumor were the two prognostic factors. Results: The 5-year OS was 78.1% in responders, and 63.4% in nonresponders. In addition the 5-year DSS was 85.1% in responders, and 72.9% in nonresponders. Conclusion: Based on SEER database in locally advanced rectosigmoid junction cancer, patients with a good response to neoadjuvant chemoradiotherapy could have a benefit of long-term survival.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijph.v52i9.13575","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neoadjuvant chemoradiotherapy is recommended to locally advanced rectal cancer, especially for the lower and middle ones. However, the role of neoadjuvant chemoradiotherapy in rectosigmoid junction cancer remains undetermined. We investigated whether patients with a good response to neoadjuvant chemoradiotherapy will have a relatively better long-term survival compared with those with no response. Methods: Overall, 1325 patients diagnosed with locally advanced rectosigmoid junction cancer from Surveillance, Epidemiology, and End-Results (SEER) cancer registry database (2004-2014, America) were selected. All of them had received neoadjuvant chemoradiotherapy and were evaluated by Collaborative Stage Data Collection System. We performed Kaplan–Meier univariate analysis and Cox regression multivariate analysis models to estimate the potential prognostic factors of long-term survival outcomes. Response to neoadjuvant chemoradiotherapy and histological type of tumor were the two prognostic factors. Results: The 5-year OS was 78.1% in responders, and 63.4% in nonresponders. In addition the 5-year DSS was 85.1% in responders, and 72.9% in nonresponders. Conclusion: Based on SEER database in locally advanced rectosigmoid junction cancer, patients with a good response to neoadjuvant chemoradiotherapy could have a benefit of long-term survival.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对新辅助放化疗的反应作为局部晚期直肠乙状结癌患者长期生存的预测指标:基于SEER数据库的分析

背景:局部进展期直肠癌，尤其是下、中期直肠癌，推荐采用新辅助放化疗。然而，新辅助放化疗在直肠乙状结肠结癌中的作用仍未确定。我们调查了对新辅助放化疗反应良好的患者是否比无反应的患者有相对更好的长期生存。方法:从2004-2014年美国SEER癌症登记数据库中选择1325例诊断为局部晚期直肠乙状结肠结癌的患者。所有患者均接受了新辅助放化疗，并通过协同分期数据收集系统进行评估。我们采用Kaplan-Meier单因素分析和Cox回归多因素分析模型来估计长期生存结果的潜在预后因素。对新辅助放化疗的反应和肿瘤的组织学类型是影响预后的两个因素。结果:应答者5年OS为78.1%，无应答者为63.4%。此外，缓解者的5年DSS为85.1%，无缓解者为72.9%。结论:基于SEER数据库的局部晚期直肠乙状结癌患者，对新辅助放化疗反应良好的患者可获得长期生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.